Test Catalog

Test Id : IGFGP

Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor-Binding Protein 3 Growth Panel, Serum

Useful For
Suggests clinical disorders or settings where the test may be helpful

Diagnosing growth disorders


Diagnosing adult growth hormone deficiency


Monitoring of recombinant human growth hormone treatment


Insulin-like growth factor binding protein 3 can be used as a possible adjunct to insulin-like growth factor 1 and growth hormone in the diagnosis and follow-up of acromegaly and gigantism.

Profile Information
A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.

Test Id Reporting Name Available Separately Always Performed
IGFB3 IGFBP-3, S Yes Yes

Method Name
A short description of the method used to perform the test

IGFMS: Liquid Chromatography-Mass Spectrometry (LC-MS)

IGFB3: Enzyme-Labeled Chemiluminescent Immunometric Assay

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.


Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

IGF-1 LC/MS, IGFBP-3 Growth Panel

Lists additional common names for a test, as an aid in searching

IGF (Insulin-LIike Growth Factor)



Insulin Like Growth Factor I

Insulin-like Growth Factor Binding

Somatomedin C binding protein


Specimen Type
Describes the specimen type validated for testing


Necessary Information

Indicate patient's age and sex.

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Collection Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: 2 Plastic vials

Specimen Volume: 1 mL

Collection Instructions:

1. Centrifuge promptly.

2. Aliquot into 2 plastic vials in equal portions.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

0.5 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Gross hemolysis Reject
Gross lipemia OK

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Serum Frozen 14 days

Useful For
Suggests clinical disorders or settings where the test may be helpful

Diagnosing growth disorders


Diagnosing adult growth hormone deficiency


Monitoring of recombinant human growth hormone treatment


Insulin-like growth factor binding protein 3 can be used as a possible adjunct to insulin-like growth factor 1 and growth hormone in the diagnosis and follow-up of acromegaly and gigantism.

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Insulin-like growth factor 1 (IGF1) is a 70-amino acid polypeptide (molecular weight 7.6 kDa). IGF1 is a member of a family of closely related growth factors with high homology to insulin that signal through a corresponding group of highly homologous tyrosine kinase receptors. IGF1 is produced by many tissues, but the liver is the main source of circulating IGF1. IGF1 is the major mediator of the anabolic and growth-promoting effects of growth hormone (GH). IGF1 is transported by IGF-binding proteins, in particular insulin-like growth factor-binding protein 3 (IGFBP3), which also controls its bioavailability and half-life.


IGFBP3 is a 264-amino acid peptide (MW 29kD) produced by the liver. It is the most abundant of a group of IGFBPs that transport, and control bioavailability and half-life of IGFs, in particular IGF1, the major mediator of the anabolic- and growth-promoting effects of GH. In addition to its IGF binding-function, IGFBP3 also exhibits intrinsic growth-regulating effects that are not yet fully understood, but have evoked interest with regards to a possible role of IGFBP3 as a prognostic tumor marker.


Noncomplexed IGF1 and IGFBP3 have short half-lives (t1/2) of 10 and 30 to 90 minutes, respectively, while the IGFBP3/IGF1 complex is cleared with a much slower t1/2 of 12 hours.


The secretion patterns of IGF1 and IGFBP3 mimic each other, their respective syntheses being controlled by GH. Unlike GH secretion, which is pulsatile and demonstrates significant diurnal variation, IGF1 and IGFBP3 levels show only minor fluctuations. IGF1 and IGFBP3 serum levels, therefore, represent a stable and integrated measurement of GH production and tissue effect.


Low IGF1 and IGFBP3 levels are observed in GH deficiency or GH resistance. If acquired in childhood, these conditions result in short stature.


Childhood GH deficiency can be an isolated abnormality or associated with deficiencies of other pituitary hormones. Some of the latter cases may be due to pituitary or hypothalamic tumors, or result from cranial radiation or intrathecal chemotherapy for childhood malignancies.


Most GH resistance in childhood is mild to moderate, with causes ranging from poor nutrition to severe systemic illness (eg, renal failure). These individuals may have IGF1 and IGFBP3 levels within the reference range. Severe childhood GH resistance is rare and usually due to defects of the GH-receptor, its downstream signaling cascades, or deleterious mutations in IGF1, its binding proteins, or its receptor signaling cascades.


Both GH deficiency and mild-to-moderate GH resistance can be treated with recombinant human GH (rhGH) injections, while severe resistance will usually not respond to GH. However, such patients might respond to recombinant IGF1 therapy, unless the underlying defect is in the IGF1 receptor or its downstream signaling systems.


The exact prevalence and causes of adult GH resistance are uncertain, but adult GH deficiency is seen mainly in pituitary tumor patients. It is associated with decreased muscle bulk and increased cardiovascular morbidity and mortality, but replacement therapy remains controversial.


Elevated serum IGF1 and IGFBP3 levels often indicate a sustained overproduction of GH, or excessive rhGH therapy. Endogenous GH excess is caused mostly by GH-secreting pituitary adenomas, resulting in gigantism, if acquired before epiphyseal closure, and in acromegaly thereafter. Both conditions are associated with generalized organomegaly, hypertension, diabetes, cardiomyopathy, osteoarthritis, compression neuropathies, a mild increase in cancer risk (breast, colon, prostate, lung), and diminished longevity. It is plausible, but unproven, that long-term rhGH overtreatment may result in similar adverse outcomes.


Malnutrition results in low serum IGF1 concentrations, which recover with restoration of adequate nutrition.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.



0-11 months: 18-156 ng/mL

1 year: 14-203 ng/mL

2 years: 16-222 ng/mL

3 years: 22-229 ng/mL

4 years: 30-236 ng/mL

5 years: 39-250 ng/mL

6 years: 47-275 ng/mL

7 years: 54-312 ng/mL

8 years: 61-356 ng/mL

9 years: 67-405 ng/mL

10 years: 73-456 ng/mL

11 years: 79-506 ng/mL

12 years: 84-551 ng/mL

13 years: 90-589 ng/mL

14 years: 95-618 ng/mL

15 years: 99-633 ng/mL

16 years: 104-633 ng/mL

17 years: 107-615 ng/mL

18-22 years: 91-442 ng/mL

23-25 years: 66-346 ng/mL

26-30 years: 60-329 ng/mL

31-35 years: 54-310 ng/mL

36-40 years: 48-292 ng/mL

41-45 years: 44-275 ng/mL

46-50 years: 40-259 ng/mL

51-55 years: 37-245 ng/mL

56-60 years: 34-232 ng/mL

61-65 years: 33-220 ng/mL

66-70 years: 32-209 ng/mL

71-75 years: 32-200 ng/mL

76-80 years: 33-192 ng/mL

81-85 years: 33-185 ng/mL

86-90 years: 33-179 ng/mL

> or=91 years: 32-173 ng/mL



0-11 months: 14-192 ng/mL

1 year: 23-243 ng/mL

2 years: 28-256 ng/mL

3 years: 31-249 ng/mL

4 years: 33-237 ng/mL

5 years: 36-234 ng/mL

6 years: 39-246 ng/mL

7 years: 44-279 ng/mL

8 years: 51-334 ng/mL

9 years: 61-408 ng/mL

10 years: 73-495 ng/mL

11 years: 88-585 ng/mL

12 years: 104-665 ng/mL

13 years: 120-719 ng/mL

14 years: 136-729 ng/mL

15 years: 147-691 ng/mL

16 years: 153-611 ng/mL

17 years: 149-509 ng/mL

18-22 years: 85-370 ng/mL

23-25 years: 73-320 ng/mL

26-30 years: 66-303 ng/mL

31-35 years: 59-279 ng/mL

36-40 years: 54-258 ng/mL

41-45 years: 49-240 ng/mL

46-50 years: 44-227 ng/mL

51-55 years: 40-217 ng/mL

56-60 years: 37-208 ng/mL

61-65 years: 35-201 ng/mL

66-70 years: 34-194 ng/mL

71-75 years: 34-187 ng/mL

76-80 years: 34-182 ng/mL

81-85 years: 34-177 ng/mL

86-90 years: 33-175 ng/mL

> or =91 years: 25-179 ng/mL


Tanner Stage reference ranges:


Stage I: 81-255 ng/mL

Stage II: 106-432 ng/mL

Stage III: 245-511 ng/mL

Stage IV: 223-578 ng/mL

Stage V: 227-518 ng/mL



Stage I: 86-323 ng/mL

Stage II: 118-451 ng/mL

Stage III: 258-529 ng/mL

Stage IV: 224-586 ng/mL

Stage V: 188-512 ng/mL


Tanner Stage reference source: Bindlingmaier M, Friedrich N, Emeny RT, et al: Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014 May;99(5):1712-1721


Note: Puberty onset (transition from Tanner stage I to Tanner stage II) occurs for boys at a median age of 11.5 (+/-2) years and for girls at a median age of 10.5 (+/-2) years. There is evidence that it may occur up to 1 year earlier in obese girls and in African American girls. For boys, there is no definite proven relationship between puberty onset and body weight or ethnic origin. Progression through Tanner stages is variable. Tanner stage V (young adult) should be reached by age 18.



1-7 days: < or =0.7 mcg/mL

8-14 days: 0.5-1.4 mcg/mL

15 days-11 months: unavailable

1 year: 0.7-3.6 mcg/mL

2 years: 0.8-3.9 mcg/mL

3 years: 0.9-4.3 mcg/mL

4 years: 1.0-4.7 mcg/mL

5 years: 1.1-5.2 mcg/mL

6 years: 1.3-5.6 mcg/mL

7 years: 1.4-6.1 mcg/mL

8 years: 1.6-6.5 mcg/mL

9 years: 1.8-7.1 mcg/mL

10 years: 2.1-7.7 mcg/mL

11 years: 2.4-8.4 mcg/mL

12 years: 2.7-8.9 mcg/mL

13 years: 3.1-9.5 mcg/mL

14 years: 3.3-10 mcg/mL

15 years: 3.5-10 mcg/mL

16 years: 3.4-9.5 mcg/mL

17 years: 3.2-8.7 mcg/mL

18 years: 3.1-7.9 mcg/mL

19 years: 2.9-7.3 mcg/mL

20 years: 2.9-7.2 mcg/mL

21-25 years: 3.4-7.8 mcg/mL

26-30 years: 3.5-7.6 mcg/mL

31-35 years: 3.5-7.0 mcg/mL

36-40 years: 3.4-6.7 mcg/mL

41-45 years: 3.3-6.6 mcg/mL

46-50 years: 3.3-6.7 mcg/mL

51-55 years: 3.4-6.8 mcg/mL

56-60 years: 3.4-6.9 mcg/mL

61-65 years: 3.2-6.6 mcg/mL

66-70 years: 3.0-6.2 mcg/mL

71-75 years: 2.8-5.7 mcg/mL

76-80 years: 2.5-5.1 mcg/mL

81-85 years: 2.2-4.5 mcg/mL


Tanner Stages:


Stage I: 1.4-5.2 mcg/mL

Stage II: 2.3-6.3 mcg/mL

Stage III: 3.1-8.9 mcg/mL

Stage IV: 3.7-8.7 mcg/mL

Stage V: 2.6-8.6 mcg/mL



Stage I: 1.2-6.4 mcg/mL

Stage II: 2.8-6.9 mcg/mL

Stage III: 3.9-9.4mcg/mL

Stage IV: 3.3-8.1 mcg/mL

Stage V: 2.7-9.1 mcg/mL


Note: Puberty onset, ie, the transition from Tanner stage 1 (prepubertal) to Tanner stage 2 (early pubertal), occurs for girls at a median age of 10.5 (+/-2) years and for boys at a median age of 11.5 (+/-2) years. There is evidence that it may occur up to 1 year earlier in obese girls and in African-American girls. By contrast, for boys there is no definite proven relationship between puberty onset and body weight or ethnic origin. Progression through Tanner stages is variable. Tanner stage 5 (young adult) should be reached by age 18.

Provides information to assist in interpretation of the test results

Both insulin-like growth factor 1 (IGF1) and insulin-like growth factor binding protein 3 (IGFBP3) measurements can be used to assess growth hormone (GH) excess or deficiency. However, for all applications, IGF1 measurement has generally been shown to have superior diagnostic sensitivity and specificity, and should be used as the primary test. In particular, in the diagnosis and follow-up of acromegaly and gigantism, IGFBP3 measurement adds little if anything to IGF1 testing.


The combination of IGF1 and IGFBP3 measurements might offer some benefits over either analyte alone in the diagnosis of GH deficiency and resistance, and in the monitoring of recombinant human GH (rhGH) therapy.


Serum IGF1 and IGFBP3 concentrations below the 2.5th percentile (Standard deviation score, Z-score of <-2) for age are consistent with GH deficiency or severe GH resistance, but patients with incomplete GH deficiency or mild-to-moderate GH resistance may have levels within the reference range. In GH deficiency, GH levels may also be low and can show suboptimal responses in stimulation tests (eg exercise, clonidine, arginine, ghrelin, growth hormone-releasing hormone, insulin-induced hypoglycemia), while in severe GH resistance, GH levels might be substantially elevated. However, dynamic GH testing is not always necessary for diagnosis. If it is undertaken, it should be performed and interpreted in endocrine testing centers under the supervision of a pediatric or adult endocrinologist.


The aim of both pediatric and adult GH replacement therapy is to achieve IGF1 and IGFBP3 levels within the reference range, ideally within the middle-to-upper third. Higher levels are rarely associated with any further therapeutic gains, but could potentially lead to long-term problems of GH excess.


Elevated IGF1 and IGFBP3 levels support the diagnosis of acromegaly or gigantism in individuals with appropriate symptoms or signs. In successfully treated patients, both levels should be within the normal range, ideally within the lower third. In both diagnosis and follow-up, IGF1 levels correlate better with clinical disease activity than IGFBP3 levels.


After transsphenoidal removal of pituitary tumors in patients with acromegaly, IGF-I concentration starts to decrease and returns to normal levels in most patients postoperatively by the fourth day.


Persons with anorexia or malnutrition have low values of IGF1. IGF1 is a more sensitive indicator than prealbumin, retinol-binding protein, or transferrin for monitoring nutritional repletion.

Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Insulin-like growth factor 1 (IGF1) and insulin-like growth factor-binding protein 3 (IGFBP3) reference ranges are highly age dependent and results must always be interpreted within the context of the patient's age.


During normal pregnancy, serum IGF1 increases on average almost 2-fold (range approximately 1.1-fold to approximately 4-fold) over prepregnancy baseline concentrations; however, reference ranges on this population have not been formally established in our institution.


Discrepant IGF1 and IGFBP3 results can sometimes occur due to liver and kidney disease; however, this is uncommon and such results should alert laboratories and physicians to the possible occurrence of a pre-analytical or analytical error.


Currently, IGF1 or IGFBP3 IGF1 cannot be reliably used as risk indicators or prognostic markers in breast, colon, prostate, or lung cancer.


IGF1 assays exhibit significant variability among platforms and manufacturers. Direct comparison of results obtained by different assays is problematic. If IGF1 and IGFBP3 are being used for serial monitoring, rebaselining of patients is preferred if assays are changed.


Several amino acid polymorphisms within IGF1 have been discovered. At least 4 of these are known to result in IGF1 isoforms with diminished biological activity. IGF1 immunoassays vary in their ability to detect these reduced-function mutants. If they do detect the mutants, then this will result in an overestimation of functionally active IGF1 in an affected patient. By contrast, a mass spectrometry (MS)-based IGF1 assay can usually selectively detect the active IGF1 isoforms. However, there might be as yet unknown functionally different variants of IGF1, which even MS cannot distinguish from wild-type (normal) IGF1.


Since the IGFBP3 assay is an immunometric assay, heterophile antibody interferences can rarely cause erroneous results, usually false-high. Heterophile antibodies in human serum can react with the immunoglobulins included in the assay components causing interference with immunoassays. Specimens from patients with autoimmune diseases or from individuals routinely exposed to animals or animal serum products can demonstrate this type of interference, potentially causing an anomalous result. The assay reagents have been formulated to minimize the risk of such interference; however, rare interactions can occur. For diagnostic purposes, the results obtained from this assay should always be used in combination with the clinical examination, patient medical history, and other findings.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Wetterau L, Cohen P: Role of insulin-like growth factor monitoring in optimizing growth hormone therapy. J Ped Endocrinol Metab. 2000;13:1371-1376

2. Granada ML, Murillo J, Lucas A, et al: Diagnostic efficiency of serum IGF-1, IGF-binding protein-3 (IGFBP-3), IGF/IGFBP-3 molar ratio and urinary GH measurements in the diagnosis of adult GH deficiency: importance of an appropriate reference population. Eur J Endocrinol. 2000;142:243-253

3. Parama C, Fluiters E, de la Fuente J, et al: Monitoring of treatment success in patients with acromegaly: the value of serum insulin-like growth factor binding protein-3 and serum leptin measurements in comparison to plasma insulin-like growth factor 1 determination. Metabolism. 2001;50:1117-1121

4. Monzavi R, Cohen P: IGFs and IGFBPs: role in health and disease. Best Pract Res Clin Endocrinol Metab. 2002;16:433-447

5. Boquete HR, Sobrado PG, Fideleff HL, et al: Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-1 and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis. J Endocrinol Metab. 2003;88:4702-4708

6. Brabant G: Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. Eur J Endocrinol. 2003;148:S15-S20

7. Boscato LM, Stuart MC: Heterophilic antibodies: a problem for all immunoassays. Clin Chem. 1988;34:27-33

Method Description
Describes how the test is performed and provides a method-specific reference

Insulin-Like Growth Factor 1:

Stable isotope labeled internal standard is added to patient samples. Insulin-like growth factor 1 (IGF1) is then extracted by selective precipitation. The extracted samples are analyzed by liquid chromatography-mass spectrometry. This is a laboratory-developed MS test, calibrated against the First World Health Organization International standard for IGF1 (02/254).(Unpublished Mayo method)


Insulin-Like Growth Factor-Binding Protein 3:

The IMMULITE 2000 IGFBP3 (insulin-like growth factor-binding protein 3) is a solid-phase, enzyme-linked chemiluminescent immunoassay based on murine monoclonal antibodies. The patient sample and alkaline phosphatase-conjugated anti-IGFBP3 antibodies are simultaneously incubated with an antibody-coated bead. During this time, IGFBP3 in the sample forms an antibody sandwich complex that binds to the streptavidin on the bead. Unbound enzyme conjugate is then removed by washing, after which substrate is added. The chemiluminescent substrate, a phosphate ester of adamantyl dioxetane, undergoes hydrolysis in the presence of alkaline phosphatase to yield an unstable intermediate. The continuous production of this intermediate results in the sustained emission of light. The photon output is directly proportional to the concentration of IGFBP-3 in the sample.(Package insert: IMMULITE 2000 IGFBP-3. Siemens Healthcare Diagnostics; PIL2KGB-15. 03/2018)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information


Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

IGFB3: Monday through Friday, Saturday

IGFMS: Monday through Friday, Sunday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

2 to 5 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

14 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test


Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

See Individual Test IDs

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.



LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
IGFGP IGF-1 LC/MS, IGFBP-3 Growth Panel In Process
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
IGFB3 IGFBP-3, S 2483-6
62750 IGF-1, LC/MS, S 2484-4
35781 Z-score 73561-3

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports